Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Bevacizumab
Drug: Cisplatin
Drug: Docetaxel

First Posted Date: 2008-04-18

Last Posted Date: 2014-07-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 50

Registration Number: NCT00661778

A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: Methoxy polyethylene glycol-epoetin beta

First Posted Date: 2008-04-17

Last Posted Date: 2016-03-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 124

Registration Number: NCT00660023

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Phase 3

Completed

Conditions: Coronary Heart Disease

Interventions: Drug: Dalcetrapib (RO4607381)
Drug: Evidence-based medical care for Acute Coronary Syndrome
Drug: Placebo

First Posted Date: 2008-04-15

Last Posted Date: 2020-01-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 15871

Registration Number: NCT00658515

A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients

Phase 2

Completed

Conditions: Coronary Heart Disease

Interventions: Drug: Placebo
Drug: dalcetrapib

First Posted Date: 2008-04-10

Last Posted Date: 2020-01-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 476

Registration Number: NCT00655538

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

Phase 2

Completed

Conditions: Coronary Heart Disease

Interventions: Drug: Placebo
Drug: Dalcetrapib (RO4607381)

First Posted Date: 2008-04-10

Last Posted Date: 2020-01-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 130

Registration Number: NCT00655473

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Erlotinib, escalating dose
Drug: Erlotinib, standard dose
Drug: Gemcitabine

First Posted Date: 2008-04-03

Last Posted Date: 2015-02-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 467

Registration Number: NCT00652366

PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients)

Not Applicable

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Device: Accu-Chek Aviva Meter

First Posted Date: 2008-03-26

Last Posted Date: 2016-03-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1000

Registration Number: NCT00643474

A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: Standard chemotherapy
Drug: bevacizumab [Avastin]

First Posted Date: 2008-03-26

Last Posted Date: 2019-10-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 154

Registration Number: NCT00643565

Locations: 🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇧🇪
Hôpital Enfants Reine Fabiola, Bruxelles, Belgium
🇧🇪
UZ Gent, Gent, Belgium

and more 58 locations

A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Phase 2

Terminated

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Standard chemotherapy
Drug: bevacizumab [Avastin]

First Posted Date: 2008-03-25

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 3

Registration Number: NCT00642824

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: bevacizumab [Avastin]
Drug: irinotecan
Drug: leucovorin
Drug: fluorouracil

First Posted Date: 2008-03-25

Last Posted Date: 2022-12-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 214

Registration Number: NCT00642577

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy